References
- Oldenburg CE, Seage GR, Tanser F, et al. Antiretroviral therapy and mortality in rural South Africa: a comparison of causal modeling approaches. Am J Epidemiol. 2018; Forthcoming. doi:10.1093/aje/kwy065.
- Oldenburg CE, Moscoe E, Barnighausen T. Regression discontinuity for causal effect estimation in epidemiology. Curr Epidemiol Rep. 2016;3(3):1–9. doi:10.1007/s40471-016-0080-x.
- Bor J, Moscoe E, Mutevedzi P, Newell M-L, Barnighausen T. Regression discontinuity designs in epidemiology. Epidemiology. 2014;25(5):729–737. doi:10.1097/EDE.0000000000000138.
- Moscoe E, Bor J, Barnighausen T. Regression discontinuity designs are underutilized in medicine, epidemiology, and public health: a review of current and best practice. J Clin Epidemiol. 2015;68(2):132–143. doi:10.1016/j.jclinepi.2014.06.021.
- Vandenbroucke JP, Le Cessie S. Regression discontinuity design: let’s give it a try to evaluate medical and public health interventions. Epidemiology. 2014;25(5):738–741. doi:10.1097/EDE.0000000000000145.
- Shoag J, Halpern J, Eisner B, et al. Efficacy of prostate-specific antigen screening: use of the regression discontinuity in the PLCO cancer screening trial. JAMA Oncol. 2015;1(7):984–986. doi:10.1001/jamaoncol.2015.2993.
- Bor J, Fox MP, Venkataramani A, Tanser F, Pillay D, Bärnighausen T. Treatment Eligibility and Retention in Clinical HIV Care: Regression-Discontinuity Evidence from South Africa. PLoS Med. 2017;14(11):e1002463.
- Labrecque JA, Kaufman JS. Commentary. Epidemiology. 2016;27(4):500–502. doi:10.1097/EDE.0000000000000485.
- Bor J, Moscoe E, Barnighausen T. Three approaches to causal inference in regression discontinuity designs. Epidemiology. 2015;26(2):e28. doi:10.1097/EDE.0000000000000231.
- Prajna NV, Krishnan T, Mascarenhas J, et al. The Mycotic Ulcer Treatment Trial: a randomized trial comparing natamycin vs voriconazole. JAMA Ophthalmol. 2013;131(4):422. doi:10.1001/jamaophthalmol.2013.1497.
- Prajna NV, Krishnan T, Rajaraman R, et al. Mycotic Ulcer Treatment Trial II Group. Effect of Oral Voriconazole on Fungal Keratitis in the Mycotic Ulcer Treatment Trial II (MUTT II): A Randomized Clinical Trial. JAMA Ophthalmol. 2016;134(12):1365–1372.
- Oldenburg CE, Bor J, Harling G, et al. Impact of early antiretroviral therapy eligibility on HIV acquisition. Aids. 2018;32:635–643. doi:10.1097/QAD.0000000000001737.
- Smith LM, Strumpf EC, Kaufman JS, Lofters A, Schwandt M, Levesque LE. The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts. Pediatrics. 2015;135(5):e1131–e1140. doi:10.1542/peds.2014-2961.
- Barnighausen T, Oldenburg C, Tugwell P, et al. Quasi-experimental study designs series – paper 7: assessing the assumptions. J Clin Epidemiol. 2017 March;1–29. doi:10.1016/j.jclinepi.2017.02.017.
- Smith LM, Kaufman JS, Strumpf EC, Levesque LE. Effect of human papillomavirus (HPV) vaccination on clinical indicators of sexual behaviour among adolescent girls: the Ontario Grade 8 HPV Vaccine Cohort Study. Cmaj. 2015;187(2):E74–E81. doi:10.1503/cmaj.
- Hernan MA, Taubman SL. Does obesity shorten life? The importance of well-defined interventions to answer causal questions. Int J Obes Relat Metab Disord. 2008;32:S8–S14. doi:10.1038/ijo.2008.82.
- Lalitha P, Sun CQ, Prajna NV, et al. In vitro susceptibility of filamentous fungal isolates from a corneal ulcer clinical trial. Am J Ophthalmol. 2014;157(2):318–326. doi:10.1016/j.ajo.2013.10.004.
- Kaptchuk TJ, Miller FG. Placebo effects in medicine. N Engl J Med. 2015;373(1):8–9. doi:10.1056/NEJMp1506446.